Keyword: Todd Hobbs

3. Semaglutide

Novo Nordisk is hoping that its new weekly GLP-1 diabetes drug semaglutide can grab the blockbuster baton from daily-dosed predecessor Victoza—and it's counting on outcomes data to help make that happen.